T1	p 72 123	zoster vaccine in healthy adults ?60 years of age .
T2	p 512 538	210 subjects ?60 years old
T3	p 1674 1696	adults ?60 years old .
T4	i 604 812	ZV , separated by 6 weeks , vs. placebo . Immunogenicity was evaluated using VZV interferon-gamma ( IFN-? ) enzyme-linked immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody
T5	i 1304 1311	placebo
T6	i 1500 1507	placebo
T7	o 6 48	Safety , tolerability , and immunogenicity
T8	o 646 660	Immunogenicity
T9	o 726 860	immunospot ( ELISPOT ) assay and VZV glycoprotein enzyme-linked immunosorbent antibody ( gpELISA ) assay . Adverse experiences ( AEs )
T10	o 880 918	standardized Vaccination Report Card .
T11	o 930 957	serious vaccine-related AEs
T12	o 969 1085	VZV IFN-? ELISPOT geometric mean count ( GMC ) of spot-forming cells per 10 ( 6 ) peripheral blood mononuclear cells
T13	o 1356 1377	peak ELISPOT response
T14	o 1421 1459	gpELISA geometric mean titers ( GMTs )
T15	o 1567 1599	IFN-? ELISPOT and gpELISA assays
T16	o 1640 1670	well-tolerated and immunogenic